SynAct Pharma AB
STO:SYNACT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
SynAct Pharma AB
STO:SYNACT
|
SE |
|
FLEX LNG Ltd
OSE:FLNG
|
BM |
|
P
|
Propel Funeral Partners Ltd
ASX:PFP
|
AU |
|
T
|
Twin Vee PowerCats Co
NASDAQ:VEEE
|
US |
|
E
|
Encavis AG
XBER:ECV
|
DE |
|
Low Keng Huat (Singapore) Ltd
SGX:F1E
|
SG |
|
Chicago Atlantic BDC Inc
NASDAQ:LIEN
|
US |
|
R
|
Rocca SA
WSE:RCA
|
PL |
|
S
|
SRM Entertainment Inc
NASDAQ:SRM
|
US |
|
Faraday Copper Corp
TSX:FDY
|
CA |
|
Hempacco Co Inc
OTC:HPCO
|
US |
|
H
|
Hantop Inc
KOSDAQ:002680
|
KR |
|
B
|
Belluscura PLC
LSE:BELL
|
UK |
|
Lottery.com Inc
NASDAQ:LTRY
|
US |
|
TietoEVRY Corp
F:TTEB
|
FI |
|
Qilian International Holding Group Ltd
NASDAQ:QLI
|
CN |
|
Schaffer Corporation Ltd
ASX:SFC
|
AU |
|
Enwave Corp
XTSX:ENW
|
CA |
|
M
|
Mlabs Systems Bhd
KLSE:MLAB
|
MY |
|
Probiotec Ltd
ASX:PBP
|
AU |
Bankruptcy Probability
SynAct Pharma AB's probability of bankruptcy is hidden . The solvency score is hidden .
We take all the information about a company's solvency (such as how easily a company can pay interest on its outstanding debt, how much cash it has, the amount of debt, and more) and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
SynAct Pharma AB Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SE |
S
|
SynAct Pharma AB
STO:SYNACT
|
971.7m SEK |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
369.2B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.5B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
173.4B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.4B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.5B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
67B AUD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
39.6B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
SynAct Pharma AB's probability of bankruptcy is hidden .
The probability of bankruptcy is estimated using credit risk models that assess its financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, SynAct Pharma AB has total debt of 595k SEK. This includes both short-term (0 SEK) and long-term (595k SEK) debt.
You can find a full breakdown on its Balance Sheet.
